Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan [1]

AIDS

Volumn 19, Issue 17, 2005, Pages 2043-2044

  Corona, Giuseppe ^a   Vaccher, Emanuela ^a   Cattarossi, Giulio ^a   Sartor, Ivana ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; ONDANSETRON;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; NEUTROPENIA; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 27944485304     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000180790.77379.3a     Document Type: Letter

References (8)

1. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91:155-163.
2. Vaccher E, Spina M, Talamini R, Zanetti M, di Gennaro G, Nasti G, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1556-1564.
3. Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943-2947.
4. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-2178.
5. Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J, Nooter K. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 1998; 712:225-235.
6. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182-2194.
7. Sommadossi JP. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS 1999; 13 (Suppl. 1):S29-S40.
8. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20:3122-3129.